Upéicharamo jepe, tasa de mortalidad iñambue tuichaháicha peteĩ región-gui ambuépe, África Occidental oreko quinto riesgo yvatevéva cáncer de próstata rehegua yvy ape ári, ha Nigeria oguereko población ha economía tuichavéva ko región-pe.
Nigeria-pe, cáncer de próstata hína pe cáncer ojehechavéva ha oporojukáva kuimba'épe, oje'e oĩha 32,8 káso ha 16,3 omanóva 100.000 kuimba'épe.
Kóva ha'e mokõi jey hetave mortalidad oĩva América del Norte-pe.
Tasy jejuhu ag̃uiete, sa'i recurso ojehecha ha ojejuhu haguã, ha sa'ive kuatia ha marandu umi káso rehe, ombohape Nigeria-pe hetaiteve omano haguã.
Estados Unidos-pe, cáncer de próstata ha'e mokõiha mba'asy hetave oporojukáva kuimba'épe, amo 40.000 kuimba'e rupi omano ko mba'asýgui peteĩ ary aja.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Ñemboyke: pohã']
["Ko página web niko ñehekombo'e ha marandu rehegua añónte, ndaha'éi ñeporandu térã ñepytyvõ pohãnohárape."]
["Ko marandu oñeme'ẽva ndojeporúi va'erã ojeikuaa térã oñepohano hag̃ua peteĩ problema de salud térã mba'asy, ha umi tapicha ohekáva consejo médico ha'eñoháme oñe'ẽva'erã peteĩ pohanohára ikatupyrýva ndive."]
["DMCA ojerure ne ñemomarandu rehe ejaposégui mba'evai ejaposéva rehe toike ko'ã mba'e: (1) tembiapo ojejaposéva rehegua ha'éva mba'evai; (2) jehaipy ha mba'ekuaarã ome'ẽva oréve jehaipyre ha'éva mba'evai ha ome'ẽva oréve pa'ũ rojuhu hag̃ua; (3) ne ñanduti veve, ne rendaite, ne pumbyry papapy ha ne ñanduti veve; (4) ñe'ẽme'ẽ erekóva rejeroviaha pe mba'evai ejaposéva rehe ndojeruréiha mba'evai apohára, imaranduhára térã léi."]
["5. peteî declaración nde rejapóva, remoîva nde réra ha remoîva'erâha nde jurúpe, umi mba'e oîva ñemomarandúpe oîmbaha añetehápe ha rerekoha pokatu remoañete haguâ umi derecho oje'éva nde rehe ojepoko vaiha;"]
["Ndoikéi ramo opaite ko'ã mba'e ikatu ombohape nde denuncia ñemboguata."]
['Ñemboheraguapy']
["Remba'eporanduséramo térã ereko hag̃ua ne remiandu ehai oréve."]
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
["Mba'e rehegua"]
['BioMedLib oiporu computadora automatizada (algoritmo de aprendizaje automático) ojapo hag̃ua porandu ha mbohovái.']
